Výsledky vyhledávání - "Paul, Castellani"

Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching

Autor: Xavier, Adhoute, Marie, De Matharel, Laurent, Mineur, Guillaume, Pénaranda, Dann, Ouizeman, Clemence, Toullec, Albert, Tran, Paul, Castellani, Armelle, Rollet, Valérie, Oules, Hervé, Perrier, Si Nafa, Si Ahmed, Marc, Bourliere, Rodolphe, Anty

Publikováno v: World Journal of Gastrointestinal Oncology. 14:1510-1527

Starting a second-line systemic treatment for hepatocellular carcinoma (HCC) is a common situation. The only therapeutic options in France are two broad-spectrum tyrosine kinase inhibitors (TKIs), regorafenib (REG) and cabozantinib (CBZ), but no comp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd1153bd37db24ce97eb975299824611
https://doi.org/10.4251/wjgo.v14.i8.1510

Zobrazit plný text záznamu

Akademický článek

Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road?

Autor: Marc Bourlière, Olivia Pietri, Paul Castellani, Valérie Oules, Xavier Adhoute

Publikováno v: Therapeutic Advances in Gastroenterology, Vol 11 (2018)

The advent of oral direct-acting antiviral agents (DAAs) has dramatically improved the hepatitis C virus (HCV) treatment landscape in the last 4 years, providing cure rates over 95% with a shorter duration of treatment and a very good safety profile.

Externí odkaz: https://doaj.org/article/5967b3b832bc4585a3dfbd429aabbd4c

Zobrazit plný text záznamu

Expected outcomes and patients’ selection before chemoembolization—'Six-and-Twelve or Pre-TACE-Predict' scores may help clinicians: Real-life French cohorts results

Autor: Hervé Perrier, Jean-Pierre Bronowicki, Jean-Luc Raoul, Guillaume Penaranda, Olivier Monnet, Marc Bourlière, Edouard Larrey, Paul Castellani, Xavier Adhoute, Olivier Bayle, B. Pol, Albert Tran, Rodolphe Anty, Patrick Chevallier

Publikováno v: World Journal of Clinical Cases

BACKGROUND Careful selection of hepatocellular carcinoma (HCC) patients prior to chemoembolization treatment is a daily reality, and is even more necessary with new available therapeutic options in HCC. AIM To propose two new models to better stratif

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f56bd4f9bd85104c1fcb50b3280ad4c7
https://doi.org/10.12998/wjcc.v9.i18.4559

Zobrazit plný text záznamu

Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort

Autor: Xavier Adhoute, Hervé Perrier, P. Cassagneau, Paul Castellani, Valérie Oules, Jean-Pierre Bronowicki, Olivia Pietri, Jean-Luc Raoul, Patrick Beaurain, Olivier Monnet, Cyrille Muller, B. Pol, Guillaume Penaranda, Marc Bourlière, Olivier Bayle

Publikováno v: European Journal of Gastroenterology & Hepatology. 31:1414-1423

BACKGROUND Conventional transarterial chemoembolization (cTACE) with lipiodol is widely performed in patients with hepatocellular carcinoma (HCC) unsuitable for curative treatment. Additional tumor parameters such as HCC macroscopic appearance based

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d88340b6aff92a39c97d9692dc73ed6
https://doi.org/10.1097/meg.0000000000001420

Zobrazit plný text záznamu

Sorafenib: Experience and Better Management of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis

Autor: Paul Castellani, Marc Bourlière, Xavier Adhoute, Guillaume Penaranda, Hervé Perrier, Valérie Oules, Jean-Luc Raoul

Publikováno v: Liver Cancer

Background: Sorafenib is the first-line treatment for advanced hepatocellular carcinoma (HCC). The management of its side effects is improving. This study aimed to assess, in real life, if this translates into a better prognosis. Methods: This was a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b561be871f0ca28a35c7f70fa655acb4
https://doi.org/10.1159/000497161

Zobrazit plný text záznamu

Akademický článek

Detection of IL28B SNP DNA from buccal epithelial cells, small amounts of serum, and dried blood spots.

Autor: Philippe Halfon, Denis Ouzan, Hacène Khiri, Guillaume Pénaranda, Paul Castellani, Valerie Oulès, Asma Kahloun, Nolwenn Amrani, Lise Fanteria, Agnès Martineau, Lou Naldi, Marc Bourlière

Publikováno v: PLoS ONE, Vol 7, Iss 3, p e33000 (2012)

BACKGROUND & AIMS:Point mutations in the coding region of the interleukin 28 gene (rs12979860) have recently been identified for predicting the outcome of treatment of hepatitis C virus infection. This polymorphism detection was based on whole blood

Externí odkaz: https://doaj.org/article/4c7285d3a0a64df59029b9d5799da9ea

Zobrazit plný text záznamu

Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals

Autor: Floriane Sellier, Marc Bourlière, B. Pol, Manuela Campanile, Patrick Beaurain, Hervé Perrier, Olivier Bayle, Xavier Adhoute, Valérie Oules, G. Lefolgoc, Guillaume Penaranda, Jean-Luc Raoul, Paul Castellani, Olivier Monnet

Publikováno v: European Journal of Gastroenterology & Hepatology. 30:368-375

BACKGROUND Direct-acting antivirals (DAAs) therapy against hepatitis C viral (HCV) infection has markedly improved the sustained viral response. However, recent studies have suggested an unsuspected high rate of hepatocellular carcinoma (HCC) recurre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3824f7723baba243b7f509258f76f664
https://doi.org/10.1097/meg.0000000000001082

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání